CD24 Modulates Ectosome Formation in B Lymphocytes via PI3K/mTOR Pathways

Study Background and Research Question

Extracellular vesicles (EVs) are lipid bilayer-bound particles released by nearly all cell types and play crucial roles in intercellular communication. Among EVs, exosomes and ectosomes are distinguished primarily by their biogenesis: exosomes form within multivesicular bodies, while ectosomes bud directly from the plasma membrane. In the immune system, particularly in B lymphocytes, the function and regulation of these vesicles are not fully understood. Jafardoust et al. (2025) set out to determine the molecular mechanisms by which CD24—a glycophosphatidylinositol-linked protein involved in B cell development—controls the formation and transfer of functionally active EVs, focusing on the signaling pathways underlying ectosome release.

Key Innovation from the Reference Study

The central innovation of this work lies in elucidating a previously uncharacterized regulatory axis: CD24's control over ectosome formation operates through a PI3K/mTORC2/ROCK/actin pathway, with acid sphingomyelinase (aSMase) acting upstream of PI3K. This mechanistic insight bridges surface receptor signaling with cytoskeletal and lipid-modifying processes involved in EV biogenesis, specifically highlighting the selectivity for bioactive ectosome subpopulations rather than total EVs. This distinction is critical for understanding B cell communication and the functional heterogeneity of released vesicles.

Methods and Experimental Design Insights

The study employed a combination of bioinformatic pathway analyses, genetic and chemical inhibition strategies, advanced flow cytometry, and live cell imaging to dissect the regulatory network. Key methodological aspects included:

• Bioinformatic mapping to identify links between CD24, PI3K/AKT, and mTOR signaling components.
• Use of flow cytometry to monitor the transfer of EVs containing lipid-associated GFP and surface IgM from donor to recipient B cells, allowing quantification of EV-mediated receptor transfer.
• Chemical and genetic inhibition of PI3K, mTORC2, ROCK, and actin dynamics to probe their roles in EV formation.
• Single-EV analysis to distinguish between bioactive EV subtypes and assess uptake by recipient B cells.
• Live cell imaging to visualize membrane dynamics associated with vesiculation, specifically in response to pathway modulation.

This multifaceted approach enabled the authors to dissect the temporal and mechanistic relationships among pathway components, providing robust evidence for the involvement of the PI3K/mTORC2/ROCK/actin axis.

Core Findings and Why They Matter

The study's major findings, as reported by Jafardoust et al., include:

• CD24 stimulation selectively increases the release of bioactive ectosomes capable of delivering functional surface receptors to recipient B cells, but does not broadly increase total EV output.
• PI3K/mTORC2/ROCK/actin signaling governs this process, with acid sphingomyelinase acting as an upstream regulator driving vesicle formation and membrane budding.
• Pharmacologic inhibition of this pathway reduces the formation of bioactive ectosomes but does not significantly affect exosome production, underscoring a mechanistic distinction between these EV subtypes.
• Live imaging confirmed that both PI3K and ROCK are required for the membrane dynamics that underlie ectosome formation upon CD24 engagement.

These findings have broad implications. By mapping the pathway from CD24 stimulation through mTOR signaling and cytoskeletal remodeling, the study provides a framework for understanding how B lymphocytes regulate intercellular communication. This is especially relevant in contexts such as immune activation, tolerance, or disease states where EV-mediated transfer of surface molecules can shape immune responses.

Comparison with Existing Internal Articles

The mechanistic role of mTOR signaling uncovered in this study parallels key themes in cell signaling research highlighted in several internal resources. For example, the article "Rapamycin (Sirolimus): Precision mTOR Inhibition for Targeted Pathway Research" describes how mTOR inhibitors enable precise dissection of signaling in cancer and mitochondrial disease models. The current study's focus on PI3K/mTORC2 in B cells extends these principles to immunology, illustrating the broader utility of mTOR pathway modulators in EV biology.

Additionally, the guide "Rapamycin (Sirolimus): Advanced mTOR Inhibition in Cell Models" discusses optimizing workflows for mTOR pathway analysis. The findings from Jafardoust et al. offer a new experimental context—B lymphocyte ectosome formation—where established mTOR inhibitors like Rapamycin (Sirolimus) could be applied to dissect the intersection of signaling, cytoskeletal regulation, and vesicle biogenesis.

Limitations and Transferability

While the study robustly characterizes the CD24–PI3K/mTORC2–ROCK–aSMase pathway in murine B lymphocytes, several limitations should be considered:

• The work primarily utilizes ex vivo and in vitro systems, leaving open questions about the pathway's role during physiological or pathological immune responses in vivo.
• The specificity for ectosome—but not exosome—formation was demonstrated under defined experimental conditions; broader applicability to other immune cell types or to human B cells awaits further validation.
• Functional consequences of altered ectosome release on downstream immune events (e.g., antigen presentation or tolerance) remain to be established directly.

Nonetheless, the delineated signaling axis provides a strong conceptual and technical foundation for future studies aiming to manipulate EV-mediated immune regulation.

Protocol Parameters

• CD24 stimulation: Use anti-CD24 antibodies at 1–5 μg/mL for 30–120 min to induce EV release in cultured B lymphocytes.
• PI3K/mTOR pathway inhibition: Apply established mTOR inhibitors (e.g., Rapamycin/Sirolimus) at concentrations ranging from 0.1–20 nM, in line with the product information and relevant literature for cell-based assays.
• ROCK inhibition: Use pharmacologic ROCK inhibitors (e.g., Y-27632) at 10–20 μM, added 30 min prior to CD24 stimulation.
• Actin disruption: Apply agents such as cytochalasin D at sub-cytotoxic concentrations (e.g., 1–5 μM) for 30–60 min when probing cytoskeletal involvement in vesicle formation.
• EV quantification: Utilize flow cytometry for GFP+ EV detection; single-EV analysis is recommended for distinguishing bioactive subpopulations.

Research Support Resources

For researchers aiming to dissect the PI3K/mTOR axis in B lymphocyte extracellular vesicle biogenesis, validated reagents such as Rapamycin (Sirolimus) (SKU A8167) offer precise, potent, and specific mTOR inhibition (IC50 ~0.1 nM). This compound, available from APExBIO, is widely used to model cell proliferation suppression, apoptosis induction, and pathway modulation across immunology and cancer research, and is suitable for workflows similar to those described in Jafardoust et al. By integrating such pathway-targeted tools, researchers can further explore the dynamics of EV-mediated B cell communication and immune regulation.